Masitinib is targeted at patients who are no longer responding to hormone-sensitive prostate cancer treatments
CSIR-IGIB advances indigenous CRISPR Trials on sickle cell anaemia, anti-microbial resistance, liver fibrosis and rare disorders
The companies admitted taking part in the cartel in exchange for reduced fines but Alchem did not settle
The site, spanning approximately 25,000 square meters, is expected to commence operations by the end of 2025
Opaganib has shown potential in enhancing ARPI treatment by blocking multiple enzymes involved in cancer cell survival.
Enhance strategies to drive sustainability, global Reach and digital transformation for a trillion-dollar future
Capstan's lead asset, CPTX2309, is a targeted lipid nanoparticle (tLNP) that delivers an mRNA encoding an anti-CD19 chimeric antigen receptor (CAR) to CD8-expressing cytotoxic T cells in vivo
New findings reveal bemarituzumab plus chemotherapy significantly improves survival in advanced gastric cancer, offering hope for targeted treatment options
The approval in China is supported by a robust local clinical development program confirming the drug’s safety, tolerability, and efficacy profile
TEVIMBRA is a uniquely designed anti-PD-1 monoclonal antibody developed by BeiGene (now BeOne Medicines)
Subscribe To Our Newsletter & Stay Updated
